Biotech Innovation Could Extend Dosing Intervals, Simplify Production

Many biopharmaceuticals comprise small proteins that are quickly eliminated from the body. Scientists at the Technische Universitaet Muenchen (TUM) combine such small proteins with a kind of molecular balloon that swells and thus prolongs the half-life of the proteins in the body. The TUM spin-off XL-Protein GmbH has now started to further develop this new technology with blockbuster potential.